![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1420199
ºÏ¹Ì ³»½Ã°æ ½Ã¼ú ½ÃÀå ¿¹Ãø - Áö¿ªº° ºÐ¼® : ½Ã¼úº°, Á¦°øº°, Á¦Ç° À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°(-2030³â)North America Endoscopy Procedures Market Forecast to 2030 - Regional Analysis -By Procedures, Offering, Product Type (Disposable and Reusable), and End User (Hospitals and Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others) |
ºÏ¹Ì ³»½Ã°æ ½Ã¼ú ½ÃÀåÀº 2022³â 130¾ï 8,730¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â 226¾ï 1,124¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2022-2030³â°£ CAGRÀº 7.1%·Î ÃßÁ¤µË´Ï´Ù.
¼Òȱ⠳»°ú¿¡¼ ÀΰøÁö´É(AI)ÀÇ È°¿ëÀº ºÏ¹Ì ³»½Ã°æ ½Ã¼ú ½ÃÀåÀ» ÃËÁø
¼Òȱâ(GI) ³»½Ã°æ °Ë»ç¿¡¼ ÀΰøÁö´É(AI)ÀÇ ÀÀ¿ëÀº º¸´Ù ³ôÀº Á¤¹Ðµµ, Àϰü¼º, °í¼Óȸ¦ °¡Á®¿Í ÀÎÀû ¿À·ù¿Í ÇѰ踦 º¸¿ÏÇÏ°í ¸ðµç ¼öÁØ¿¡¼ ³»½Ã°æ °Ë»çÀÇ ÁúÀ» Çâ»ó °¡´É¼ºÀ» °®°í Àֱ⠶§¹®¿¡ Å« ÁÖ¸ñÀ» ¹Þ°í ÀÖ½À´Ï´Ù. AI´Â ¼Òȱ⠳»½Ã°æÀÇ ¹ßÀü¿¡ ȹ±âÀûÀÎ ´ëÇõ¸íÀ» °¡Á®¿Ã °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. AI´Â ¼ö¼úÀÚ °£ÀÇ ÆíÂ÷¸¦ ¾ïÁ¦ÇÏ´Â ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù. Ãʺ¸ÀÚÀÇ ³»½Ã°æ ±â»çÀÇ Á¦ÇÑµÈ °æÇè°ú °æÇèÀÌ Ç³ºÎÇÑ ³»½Ã°æ ±â»ç¶óµµ ¿À·ù¸¦ º¸¿Ï ÇÒ ¼ö ÀÖ½À´Ï´Ù. Áö³ 40³â°£ ½Äµµ¼±¾Ï(EAC)ÀÇ ÀÌȯÀ²Àº üÁß °ú´Ù°¡ Á¡Á¡ È®»êµÇ¾î ±Þ¼ÓÈ÷ »ó½ÂÇϰí ÀÖ½À´Ï´Ù. AI Áö¿øÀº ½Äµµ¼±¾Ï(EAC)ÀÇ ¹ß°ß°ú Áø´Ü °³¼±ÀÇ °üÁ¡¿¡¼ À¯¸ÁÇÑ °á°ú¸¦ º¸¿©ÁÖ¸ç, ±× °á°ú ÁøÇà±â°£¿¡ Áø´ÜµÇ¾úÀ» ¶§ ¿¹Èİ¡ ºÒ·®ÇÑ ÀÌ·± À¯ÇüÀÇ ¾Ç¼º Á¾¾ç°ú °ü·ÃµÈ »ç¸Á ºñÀ²°ú ÀÌȯÀ²À» °¨¼Ò½Ãŵ´Ï´Ù.
ij³ª´Ù ¼Òȱ⠺´ÇÐȸ(CAG)´Â AI¸¦ ´õ¿í ¹ßÀü½Ã۰í ÀÌ¿ëÀ» ÃËÁøÇϱâ À§ÇØ AIÀÇ Æ¯º° °ü½É ±×·ì(SIG)À» °á¼ºÇß½À´Ï´Ù. ÀÌ CAG AI SIGÀÇ ÇÙ½É ±×·ìÀº ij³ª´ÙÀÇ 3°³ ÁÖ¿¡ °ÉÃÄ ÀÖ´Â 5°³ ½Ã¼³ÀÇ 6¸íÀÇ ¼Òȱ⠳»°ú ÀÇ»ç·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ±×µéÀº ÄÚȣƮ ¿¬±¸¿Í ¹«ÀÛÀ§ ºñ±³ Å×½ºÆ®¸¦ »ç¿ëÇÏ¿© AI ±â¼úÀ» Æò°¡Çϱ⠽ÃÀÛÇß½À´Ï´Ù. ÇöÀç ºñµð¿À¿Í µ¥ÀÌÅÍÀÇ ¹ÙÀÌ¿À¹ðÅ©¸¦ È®¸³ÇÏ°í °Å±â¿¡¼ »õ·Î¿î AI ¼Ö·ç¼ÇÀ» âÃâÇϱâ À§ÇÑ ¿ø½Ã µ¥ÀÌÅ͸¦ ÃàÀûÇϰí ÀÖ½À´Ï´Ù. ±×·ì ȸ¿øÀÇ Ãß°¡ Ȱµ¿¿¡´Â AI Ä¿¸®Å§·³ÀÇ °³¹ß°ú ½ÃÇàÀÌ Æ÷ÇԵ˴ϴÙ. ¿Ö³ÄÇϸé Â÷¼¼´ë ¼Òȱâ Àü¹®ÀǴ ij³ª´Ù Àü¿ªÀÇ ½Ã¼³¿¡¼ AI ¼Ö·ç¼ÇÀ» °³¹ß ¹× ½Ç½ÃÇϱâ À§ÇÑ ÈÆ·ÃÀ» ¹Þ¾Æ¾ß Çϱ⠶§¹®ÀÔ´Ï´Ù. CAG AI SIG´Â ³»½Ã°æ °Ë»çÀÇ Áú°ú ȯÀÚ °á°ú¸¦ °³¼±Çϱâ À§ÇØ »õ·Î¿î ±â¼úÀÇ ÀáÀç·ÂÀ» ±Ø´ëÈÇϱâ À§ÇØ »õ·Î¿î ȸ¿ø°ú AI ¿¬±¸ÀÚ¸¦ ÃʺùÇÏ´Â °³¹æÇü ¸ðµ¨À» äÅÃÇß½À´Ï´Ù.
ÃÖ±Ù AI¸¦ Ȱ¿ëÇÑ ³»½Ã°æ Á¦Ç°ÀÌ ºÏ¹Ì¿¡¼ ÀϺΠ½ÂÀεǾú½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 11¿ù, Medtronic plcÀÇ ÀÚȸ»çÀÎ Medtronic Canada ULC´Â GI Genius Áö´ÉÇü ³»½Ã°æ ¸ðµâÀÇ Ä³³ª´Ù º¸°ÇºÎ ¶óÀ̼±½º¸¦ ÃëµæÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. GI Genius´Â ÄÄÇ»ÅÍ Áö¿ø °¨Áö(CADe) ½Ã½ºÅÛÀ¸·Î ÀΰøÁö´É(AI)À» »ç¿ëÇÏ¿© ´Ù¾çÇÑ À¯ÇüÀÇ Á¡¸· ÀÌ»ó°ú ÀÏÄ¡ÇÏ´Â ½Ã°¢Àû Ư¡À» °¡Áø °ÍÀ¸·Î ÀǽɵǴ ´ëÀå ¿µ¿ªÀ» °Á¶ Ç¥½ÃÇÕ´Ï´Ù. µû¶ó¼ ¼Òȱ⠳»°ú¿¡¼ ÀΰøÁö´É(AI)ÀÇ »ç¿ëÀº °¡±î¿î ¹Ì·¡¿¡ ³»½Ã°æ °Ë»çÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.
AI¸¦ Ȱ¿ëÇÑ ¾Ï Áø´ÜÀÇ ¼±±¸ÀÚÀÎ Ibex Medical Analytics´Â ¾ÏÀ» °ËÃâÇÏ´Â ¼¼°è ÃÖÃÊÀÇ ÀΰøÁö´É(AI) Ç÷§ÆûÀ» °³¹ßÇß½À´Ï´Ù. AI ¾Ë°í¸®ÁòÀº »ý°ËÀÇ À̹ÌÁö¸¦ ºÐ¼®Çϰí Á¾¾çÀÇ À§Ä¡¿Í ¾Ç¼ºµµ¸¦ È®ÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ °á°ú´Â º´¸® Àǻ簡 À§¾ÏÀ» Á¤È®ÇÏ°Ô Áø´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. 2021³â 6¿ù, ¹Ì±¹ ½ÄǰÀǾ౹(FDA)Àº ¾ÆÀ̺¤½ºÀÇ Galen Ç÷§Æû¿¡ ºê·¹ÀÌÅ©½º·ç µð¹ÙÀ̽º ÁöÁ¤À» ºÎ¿©ÇÏ¿© ÀÌ Ç÷§ÆûÀÇ ÀÓ»ó ½É»ç¿Í ¾à»ç ½ÂÀÎÀ» °¡¼ÓÈÇÏ°Ô µÇ¾ú½À´Ï´Ù. Galen GastricÀº À§¾Ï, ÀÌÇü¼º, H. pylori ¹× ±âŸ Áß¿äÇÑ ÀÓ»ó ¼Ò°ßÀ» °¨ÁöÇÏ´Â º´¸®ÇÐÀÚ¸¦ Áö¿øÇÏ´Â ÅëÇÕ Áø´Ü ¹× ǰÁú °ü¸® ¼Ö·ç¼ÇÀÔ´Ï´Ù.
2019³â 11¿ù ¼¼°è ÃÖÃÊÀÇ ½Ç½Ã°£ ³»½Ã°æ AI °³¹ß ±â¾÷ Áß ÇϳªÀÎ AI Medical Service Inc.´Â À§¾ÏÀÇ ÀáÀçÀû Áø´ÜÀ» À§ÇØ ³»½Ã°æ À̹ÌÁö¸¦ ºÐ¼®ÇÏ´Â AI ÇÁ·Î±×·¥¿¡ ´ëÇÑ ¹Ì±¹ FDAÀÇ Áß´Ü ½º·ç µð¹ÙÀ̽º ÁöÁ¤À» ȹµæÇß½À´Ï´Ù.
µû¶ó¼ ¾Ï Áø´ÜÀ» À§ÇÑ AI ±â¹Ý ³»½Ã°æÀÇ ÀÌ·¯ÇÑ °³¹ßÀº ¿¹Ãø ±â°£ µ¿¾È ³»½Ã°æ ½Ã¼ú ½ÃÀå¿¡ »õ·Î¿î µ¿ÇâÀ» µµÀÔÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.
ºÏ¹Ì ³»½Ã°æ ½Ã¼ú ½ÃÀå °³¿ä
ºÏ¹Ì ³»½Ã°æ ½Ã¼ú ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ¹Ì±¹ÀÌ ³»½Ã°æ°Ë»ç±â¼úÀÇ ÃÖ´ë ½ÃÀåÀ¸·Î ij³ª´Ù, ¸ß½ÃÄÚ°¡ ÀÌ¿¡ À̾îÁý´Ï´Ù. ¹Ì±¹°ú ºÏ¹Ì¿¡¼ ³·Àº ħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡¿Í ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ³»½Ã°æ ½Ã¼ú ½ÃÀåÀ» °ßÀÎ ÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ¶ÇÇÑ ¾ÖÇø®ÄÉÀ̼ÇÀÇ °È·Î À̾îÁö´Â ½ÃÀå ±â¾÷ÀÇ ±â¼úÀû Áøº¸´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
ºÏ¹Ì ³»½Ã°æ ½Ã¼ú ½ÃÀåÀÇ ¼öÀͰú ¿¹Ãø(-2030³â)(¹é¸¸ ´Þ·¯)
ºÏ¹Ì ³»½Ã°æ ½Ã¼ú ½ÃÀåÀÇ ¼¼ºÐÈ
ºÏ¹Ì ³»½Ã°æ ½Ã¼ú ½ÃÀåÀº ÀýÂ÷, Á¦°ø, Á¦Ç° À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ·Î ±¸ºÐµË´Ï´Ù.
ÀýÂ÷¿¡ µû¶ó ºÏ¹Ì ³»½Ã°æ ½Ã¼ú ½ÃÀåÀº ³»½Ã°æÀû ¿ªÇ༺ ´ã°ü ÃéÀå °üÁ¶¿µ¼ú(ERCP), ³»½Ã°æÀû Á¡¸· ÇÏÃþ ¹Ú¸®¼ú(ESD), °æ±¸ ³»½Ã°æÀû ±ÙÀý°³¼ú(POEM), ÃÊÀ½ÆÄ ³»½Ã°æ(EUS), È£Èí±â ÀÎÅͺ¥¼Ç¡¤ º¹°°æ, °üÀý°æ¡¤ ±â°üÁö°æ, ´ëÀå°æ¡¤ ´ëÀå ³»½Ã°æ, Ç×¹®°æ¡¤ Èä°°æ µîÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â ºÏ¹Ì ³»½Ã°æ ½Ã¼ú ½ÃÀå¿¡¼´Â ´Ù¸¥ ºÎ¹®ÀÌ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù.
ºÏ¹Ì ³»½Ã°æ ½Ã¼ú ½ÃÀåÀº ³»½Ã°æ, ERCP ¾×¼¼¼¸®, ½Ã°¢È ½Ã½ºÅÛ, Çìµå Æ÷Áö¼Å³Ê, ³»½Ã°æ Ä¡·á ÁÖ»ç ¹Ù´Ã, »ùÇøµ ÀåÄ¡ ÀåÄ¡ Ŭ¸³, Àü±â ¼ö¼ú Ä®, ³»½Ã°æ ÃÊÀ½ÆÄ °¡À̵å ÀåÄ¡, °¡À̵å¿ÍÀ̾î, Áý°Ô, ½º³×¾î, °ü°³/ÈíÀÔ Æ©ºê ½Ã½ºÅÛ, ÇÁ·Îºê, ÁöÇ÷ Ŭ¸³, Æú¸³ Æ®·¦, ´ÜÀÏ »ç¿ë ¹ëºê, Æ®·ÎÄ« ½½¸®ºê, Á¶Á÷ °¡À§, Ä¿ÅÍ, ȸ¼ö ÀåÄ¡ µîÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â ºÏ¹Ì ³»½Ã°æ ½Ã¼ú ½ÃÀå¿¡¼ ³»½Ã°æ ºÎ¹®Àº ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
Á¦Ç° À¯Çüº°·Î º¸¸é ºÏ¹Ì ³»½Ã°æ ½Ã¼ú ½ÃÀåÀº ÀÏȸ¿ëÀ¸·Î Àç»ç¿ë °¡´ÉÇÏ°Ô À̺е˴ϴÙ. 2022³â ºÏ¹Ì ³»½Ã°æ ½Ã¼ú ½ÃÀå¿¡¼´Â Àç»ç¿ë °¡´ÉÇÑ ºÎ¹®ÀÌ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
ÃÖÁ¾ »ç¿ëÀÚº°·Î º¸¸é, ºÏ¹ÌÀÇ ³»½Ã°æ ½Ã¼ú ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), Áø´Ü ·¦, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2022³â ºÏ¹Ì ³»½Ã°æ ½Ã¼ú ½ÃÀå¿¡¼´Â º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®ÀÌ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
±¹°¡º°·Î º¸¸é ºÏ¹Ì ³»½Ã°æ ½Ã¼ú ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ¹Ì±¹Àº 2022³â ºÏ¹Ì ³»½Ã°æ ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
Stryker Corp, Merit, Medical Systems Inc, Smith & Nephew Plc, Arthrex Inc, Steris Plc, Conmed Corp, Olympus Corp, Boston Scientific Corp, Cook Medical LLC´Â ºÏ¹Ì ³»½Ã°æ ½Ã¼ú ½ÃÀå¿¡¼ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ´ë±â¾÷ ÀÔ´Ï´Ù.
The North America endoscopy procedures market is expected to grow from US$ 13,087.30 million in 2022 to US$ 22,611.24 million by 2030. It is estimated to grow at a CAGR of 7.1% from 2022 to 2030.
Use of Artificial Intelligence (AI) in Gastroenterology Fuel to the North America Endoscopy Procedures Market
The application of artificial intelligence (AI) in gastrointestinal (GI) endoscopy is drawing a great amount of attention because it has the potential to improve the quality of endoscopy at all levels, compensating for human errors and limitations by bringing more accuracy, consistency, and higher speed. It will make a breakthrough and a big revolution in the development of GI endoscopy. AI has the advantage of limiting inter-operator variability. It can compensate for the limited experience of novice endoscopists and the errors of even the most experienced endoscopists. Over the past four decades, the incidence of esophageal adenocarcinoma (EAC) has risen rapidly due to the increasingly prevalent excess body weight. AI assistance shows promising results in terms of improving the detection and diagnosis of esophageal adenocarcinoma (EAC), thus, reducing the mortality and morbidity related to this type of malignancy with a poor prognosis when diagnosed at an advanced stage.
The Canadian Association of Gastroenterology (CAG) has formed a special interest group (SIG) in AI to further develop and promote the use of AI. This CAG AI SIG core group comprises six gastroenterologists from five Canadian institutions across three provinces. They have started evaluating AI technologies using cohort studies and randomized controlled trials. They are in the process of establishing video and data biobanks to accrue raw data from which additional novel AI solutions can be created. Further activities of group members include developing and implementing AI curricula since the next generation of gastroenterologists needs to be trained to develop and implement AI solutions at institutions across Canada. The CAG AI SIG has an open model inviting new members, and AI researchers to maximize this novel technology's potential in improving endoscopy quality and patient outcomes.
Recently, a few AI-driven endoscopy products were approved in North American region. For instance, in November 2021, Medtronic Canada ULC, a subsidiary of Medtronic plc, announced that it had received a Health Canada license for the GI Genius intelligent endoscopy module. GI Genius is a computer-aided detection (CADe) system that uses artificial intelligence (AI) to highlight regions of the colon suspected to have visual characteristics consistent with different types of mucosal abnormalities. Hence, the use of artificial intelligence (AI) in gastroenterology is likely to propel the growth of endoscopy procedures in near future.
Ibex Medical Analytics, a pioneer in AI-powered cancer diagnostics, developed the world's first artificial intelligence (AI) platform to detect cancer. Its AI algorithms analyze images of biopsies and can pinpoint their location and grade the tumor. These results help pathologists diagnose gastric cancer accurately. In June 2021, the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to Ibex's Galen platform, which will expedite the clinical review and regulatory approval of its platform. Galen Gastric is an integrated diagnostics and quality control solution that supports pathologists in the detection of gastric cancer, dysplasia, H. pylori, and other important clinical findings.
In November 2019, AI Medical Service Inc., one of the world's first real-time endoscopic AI developers, secured Breakthrough Device Designation by the US FDA for its AI programs that analyze endoscopy images for potential diagnosis of gastric cancer.
Thus, such development of AI-based endoscopes for cancer diagnostics are likely to introduce new trends in the endoscopy procedure market during the forecast period.
North America Endoscopy Procedures Market Overview
The North America endoscopy procedure market is segmented into US, Canada, and Mexico. US is the largest market for endoscopy procedure followed by Canada and Mexico. Growing preference for minimally invasive surgeries and increasing prevalence of chronic diseases in the US and North America are likely to drive the endoscopy procedure market in the forecasted period. In addition, the technological advancement by market players leading to enhanced applications is likely to foster the growth of the market in the forecasted period.
North America Endoscopy Procedures Market Revenue and Forecast to 2030 (US$ Million)
North America Endoscopy Procedures Market Segmentation
The North America endoscopy procedures market is segmented into procedure, offering, product type, and end user.
Based on procedure, the North America endoscopy procedures market is segmented into endoscopic retrograde cholangiopancreatography (ERCP), endoscopic submucosal dissection (ESD), peroral endoscopic myotomy (POEM), endoscopic ultrasound (EUS), interventional pulmonology and laparoscopy, arthroscopy and bronchoscopy, colonoscopy and colposcopy, proctoscopy and thoracoscopy, and others. The others segment held the largest share of the North America endoscopy procedures market in 2022.
Based on offering, the North America endoscopy procedures market is segmented endoscopes, ERCP accessories, visualization system, head positioner and endotherapy injection needles, sampling device and device clip and electrosurgical knife, endoscopic ultrasound guided devices, guidewire, forceps, snare, irrigation/insufflation tubing systems, probes, hemostats clip, polyps' traps, single-use valves, trocar sleeves and tissue scissors and cutters, retrieval devices, and others. The endoscopes segment held the largest share of the North America endoscopy procedures market in 2022.
Based on product type, the North America endoscopy procedures market is bifurcated into disposable and reusable. The reusable segment held a larger share of the North America endoscopy procedures market in 2022.
Based on end user, the North America endoscopy procedures market is segmented into hospitals and clinics, ambulatory surgical centres, diagnostic laboratories, and others. The hospitals and clinics segment held the largest share of the North America endoscopy procedures market in 2022.
Based on country, the North America endoscopy procedures market is segmented int o the US, Canada, and Mexico. The US dominated the North America endoscopy procedures market in 2022.
Stryker Corp, Merit, Medical Systems Inc, Smith & Nephew Plc, Arthrex Inc, Steris Plc, Conmed Corp, Olympus Corp, Boston Scientific Corp, and Cook Medical LLC are some of the leading companies operating in the North America endoscopy procedures market.